Ablation or siRNA-mediated silencing of Cdk2 and Cdk4 prevents centriole reduplication and centrosome amplification in p53−/− MEFs. (A) MEFs of the indicated genotypes were coimmunostained with antibodies recognizing pericentrin (red) (b, f, j, n, and r) and γ-tubulin (green) (c, g, k, o, and s). Nuclei were stained with DAPI (blue) (a, e, I, m, and q). (d, h, l, p, and t) Overlay images of the pericentrin and γ-tubulin immunostaining. Wt, wild type. (B) Proliferating E13.5 mouse embryonic fibroblasts of the indicated genotypes were fixed, processed, and coimmunostained with anti-pericentrin, anti-γ-tubulin, and the appropriate secondary antibodies. The graph presents averages ± standard deviations of the percentages of cells with one, two, and three or more centrosomes. Exactly 8 wild-type, 8 p53−/−, 5 p53−/− Cdk2−/−, 5 p53−/− Cdk4−/−, and 4 p53−/− Cdk2−/− Cdk4−/− embryos were analyzed. t test values for the percentage of cells in each population containing one centrosome (relative to that for the wild type) were 0.017174 for p53−/− MEFs, 0.137854 for p53−/− Cdk2−/− MEFs, 0.358121 for p53−/− Cdk4−/− MEFs, and 3.95E-05 for p53−/− Cdk2−/− Cdk4−/− MEFs. P values for the percentage of cells in each population containing two centrosomes relative to that for wild-type MEFs were 0.860687 for p53−/− MEFs, 0.9713 for p53−/− Cdk2−/− MEFs, 0.024679 for p53−/− Cdk4−/− MEFs, and 2.69E-05 for p53−/− Cdk2−/− Cdk4−/− MEFs. P values for the percentage of cells with ≥3 centrosomes relative to that for wild-type MEFs were 0.006967 for p53−/− MEFs, 0.232114 for p53−/− Cdk2−/− MEFs, 0.706722 for p53−/− Cdk4−/− MEFs, and 0.051209 for p53−/− Cdk2−/− Cdk4−/− MEFs. (C) Western blots of extracts from untransfected p53−/− MEFs or p53−/− MEFs transfected with Cdk2- or Cdk4-specific siRNAs were probed with the indicated primary antibodies. (D) Frequencies of centrosome amplification in control p53−/− MEFs and in p53−/− MEFs in which Cdk2 or Cdk4 was knocked down. Three independent MEFs were used. Centrosomes were detected as for panels A and B. The statistical significance of the averages (P ≤ 0.05) was established by an unequal-variance t test. P values for the percentage of cells with ≥3 centrosomes relative to that of control p53−/− MEFs were 0.002445 for MEFs transfected with a Cdk2-specific SiRNA and 0.006696 for MEFs transfected with a Cdk4-specific siRNA. (E) Proliferating MEFs of the indicated genotypes (3 per group) were either left untreated (NT) or treated with 2 mM HU for 48 h. To determine the presence of centrioles, the cells were subjected to cold treatment and brief extraction prior to fixation. This treatment destabilizes microtubules nucleated at centrosomes; hence, centrioles can be microscopically visualized by immunostaining for α-tubulin (a major component of centrioles) at a high magnification. Cells were coimmunostained with anti-γ-tubulin polyclonal (green) (b, f, j, and n) and anti-α-tubulin monoclonal (red) (c, g, k, and o) antibodies and were counterstained with DAPI (blue) (a, e, i, and m). (d, h, l, and p) Overlaid images of γ-tubulin and α-tubulin immunostaining. (Insets) Magnified images of the areas indicated. (F) Frequencies of centriole reduplication were established by counting cells with ≥3 separated centrioles in a population of at least 200 cells per group. P values for HU-treated compared to NT cells were 0.791492 for wild-type MEFs, 1 for p53−/− Cdk2−/− MEFs, 0.507158 for p53−/− Cdk4−/− MEFs, and 0.012161 for p53−/− MEFs.